NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis $25.95 -1.13 (-4.17%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$25.95 0.00 (0.00%) As of 08/14/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About QuidelOrtho Stock (NASDAQ:QDEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get QuidelOrtho alerts:Sign Up Key Stats Today's Range$25.53▼$26.6050-Day Range$22.81▼$31.5752-Week Range$22.05▼$49.45Volume895,927 shsAverage Volume1.64 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$42.17Consensus RatingHold Company Overview QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. Read More QuidelOrtho Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreQDEL MarketRank™: QuidelOrtho scored higher than 84% of companies evaluated by MarketBeat, and ranked 171st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageQuidelOrtho has only been the subject of 2 research reports in the past 90 days.Read more about QuidelOrtho's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.57% Earnings GrowthEarnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.78% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in QuidelOrtho has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.61 Percentage of Shares Shorted9.78% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in QuidelOrtho has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.67 News SentimentQuidelOrtho has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for QuidelOrtho this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesBiogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To KnowAugust 13 at 9:15 PM | finance.yahoo.comQDEL Q2 Deep Dive: Cost Controls and International Growth Offset Lower COVID DiagnosticsAugust 13 at 9:15 PM | finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)QuidelOrtho Launches Certified Analyzer ProgramAugust 13 at 3:00 PM | prnewswire.comQuidelOrtho’s Earnings Call: Mixed Sentiment with Global GrowthAugust 9, 2025 | theglobeandmail.comQ3 Earnings Forecast for QuidelOrtho Issued By William BlairAugust 9, 2025 | americanbankingnews.comQuidelOrtho (NASDAQ:QDEL) Shares Gap Up After Better-Than-Expected EarningsAugust 7, 2025 | americanbankingnews.comCautious Optimism: QuidelOrtho’s Hold Rating Amid Market Challenges and Margin Growth PotentialAugust 6, 2025 | tipranks.comSee More Headlines QDEL Stock Analysis - Frequently Asked Questions How have QDEL shares performed this year? QuidelOrtho's stock was trading at $44.55 at the beginning of the year. Since then, QDEL stock has decreased by 41.8% and is now trading at $25.95. How were QuidelOrtho's earnings last quarter? QuidelOrtho Corporation (NASDAQ:QDEL) posted its earnings results on Tuesday, August, 5th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.11. The firm's revenue for the quarter was down 3.6% on a year-over-year basis. Read the conference call transcript. Who are QuidelOrtho's major shareholders? Top institutional investors of QuidelOrtho include State Street Corp (3.98%), American Century Companies Inc. (2.82%), Geode Capital Management LLC (2.48%) and Invesco Ltd. (2.29%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD). Company Calendar Last Earnings8/05/2025Today8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees6,600Year Founded1979Price Target and Rating Average Price Target for QuidelOrtho$42.17 High Price Target$61.00 Low Price Target$25.00 Potential Upside/Downside+62.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($6.54) Trailing P/E RatioN/A Forward P/E Ratio11.28 P/E GrowthN/ANet Income-$2.05 billion Net Margins-16.10% Pretax Margin-14.89% Return on Equity5.29% Return on Assets2.43% Debt Debt-to-Equity Ratio0.74 Current Ratio1.12 Quick Ratio0.62 Sales & Book Value Annual Sales$2.78 billion Price / Sales0.63 Cash Flow$34.14 per share Price / Cash Flow0.76 Book Value$41.13 per share Price / Book0.63Miscellaneous Outstanding Shares67,900,000Free Float67,364,000Market Cap$1.76 billion OptionableOptionable Beta-0.04 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:QDEL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.